Brandywine Managers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brandywine Managers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Sell	3,168 -450	-12%	-$153K	0.62%	12
2025 Q4	$1.44M	Sell	3,618 -100	-3%	-$44.3K	0.71%	13
2025 Q3	$1.7M	Sell	3,718 -500	-12%	-$204K	1.63%	9
2025 Q2	$1.38M	Sell	4,218 -130	-3%	-$36K	1.37%	11
2025 Q1	$1.17M	Hold	4,348	–	–	1.41%	11
2024 Q4	$1.02M	Hold	4,348	–	–	1.08%	13
2024 Q3	$1.2M	Hold	4,348	–	–	1.29%	12
2024 Q2	$1.06M	Hold	4,348	–	–	1.12%	15
2024 Q1	$650K	Hold	4,348	–	–	0.64%	23
2023 Q4	$832K	Sell	4,348 -260	-6%	-$44.3K	0.91%	16
2023 Q3	$816K	Hold	4,608	–	–	1.38%	14
2023 Q2	$875K	Hold	4,608	–	–	0.58%	22
2023 Q1	$923K	Hold	4,608	–	–	0.66%	19
2022 Q4	$1.1M	Hold	4,608	–	–	3.83%	5
2022 Q3	$922K	Hold	4,608	–	–	3.03%	8
2022 Q2	$672K	Hold	4,608	–	–	1.65%	16
2022 Q1	$752K	Hold	4,608	–	–	1.3%	22
2021 Q4	$781K	Hold	4,608	–	–	0.89%	26
2021 Q3	$870K	Hold	4,608	–	–	0.91%	25
2021 Q2	$781K	Hold	4,608	–	–	0.89%	25
2021 Q1	$651K	Buy	4,608 +1,708	+59%	+$257K	0.87%	28
2020 Q4	$377K	Hold	2,900	–	–	0.52%	33
2020 Q3	$422K	Hold	2,900	–	–	0.8%	26
2020 Q2	$430K	Hold	2,900	–	–	1.77%	21
2020 Q1	$316K	Hold	2,900	–	–	0.11%	20
2019 Q4	$334K	Sell	2,900 -200	-6%	-$19.9K	0.1%	35
2019 Q3	$249K	Hold	3,100	–	–	0.08%	37
2019 Q2	$225K	Sell	3,100 -900	-23%	-$69.1K	0.08%	44
2019 Q1	$374K	Sell	4,000 -200	-5%	-$16.7K	0.15%	34
2018 Q4	$306K	Buy	+4,200	New	+$323K	0.14%	28

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brandywine Managers's ALNY Position: Q1 2026 in Review

Brandywine Managers reduced its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q1 2026, selling an estimated $153K and leaving 3,168 shares worth $1.05M. The position accounts for 0.62% of the portfolio, ranked #12.

Brandywine Managers first reported a position in ALNY in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.7M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Brandywine Managers held 3,168 shares of Alnylam Pharmaceuticals worth $1.05M as of Q1 2026.
Brandywine Managers sold 450 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $153K.
Alnylam Pharmaceuticals made up 0.62% of Brandywine Managers's portfolio in Q1 2026, its #12 holding.
Brandywine Managers first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
Brandywine Managers's Alnylam Pharmaceuticals position peaked at $1.7M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Brandywine Managers's 13F filing for Q1 2026, filed 14 May 2026.